Other OTC - Delayed Quote USD

Nascent Biotech, Inc. (NBIO)

0.0995 0.0000 (0.00%)
As of May 13 at 3:49 PM EDT. Market Open.
Loading Chart for NBIO
DELL
  • Previous Close 0.0995
  • Open 0.0850
  • Bid --
  • Ask --
  • Day's Range 0.0995 - 0.0995
  • 52 Week Range 0.0323 - 0.2800
  • Volume 48,200
  • Avg. Volume 48,447
  • Market Cap (intraday) 16.888M
  • Beta (5Y Monthly) -2.98
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Jun 29, 2024 - Jul 3, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

www.nascentbiotech.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NBIO

Performance Overview: NBIO

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NBIO
42.45%
S&P 500
9.91%

1-Year Return

NBIO
79.12%
S&P 500
27.13%

3-Year Return

NBIO
50.76%
S&P 500
27.48%

5-Year Return

NBIO
42.15%
S&P 500
86.45%

Compare To: NBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NBIO

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    16.89M

  • Enterprise Value

    16.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    556.13

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -233.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -2.09M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    623.85k

  • Total Debt/Equity (mrq)

    411.63%

  • Levered Free Cash Flow (ttm)

    -1.25M

Research Analysis: NBIO

Company Insights: NBIO

Research Reports: NBIO

People Also Watch